Personalis Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Basic and Diluted Net Loss Per Common Share
Note 12. Basic and Diluted Net Loss Per Common Share
Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using net loss and the weighted-average number of common shares outstanding plus potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the assumed exercise of outstanding stock options, assumed release of outstanding RSUs, assumed issuance of common stock under the ESPP, and the assumed exercise of Tempus Warrants. The Company incurred net losses in the periods presented, and as a result, potential common shares from stock options, RSUs, ESPP issuances, and the Tempus Warrants were not included in the diluted shares used to calculate net loss per share, as their inclusion would have been anti-dilutive.
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net loss | $(12,968) | $(28,659) |
| Weighted-average common shares outstanding—basic and diluted | 50,678,586 | 46,740,270 |
| Net loss per common share—basic and diluted | $(0.26) | $(0.61) |
The following table sets forth the potentially dilutive shares excluded from the computation of diluted net loss per common share because their effect was anti-dilutive:
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Tempus Warrants | 9,218,800 | — |
| Options to purchase common stock | 8,213,682 | 7,774,911 |
| Unvested RSUs | 1,047,511 | 2,197,008 |
| ESPP | 408,543 | 453,380 |
| Total | 18,888,536 | 10,425,299 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.